RU 24858 | 194413-69-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: RU 24858
• 英文别名: 3-[(8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-7,8,11,12,14,15,16,17-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-3-oxopropanenitrile
• CAS: 194413-69-9
• 化学式: C₂₃H₂₈FNO₃
• 分子量: 385.479
• InChiKey: LQHIJOQODVGHSE-UCMWIJGCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  28
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  78.2
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Steroids, their use as medicaments, their preparation process, the intermediates of this process and the compositions containing them
  申请人：Hoechst Marion Roussel

  公开号：US20020002155A1

  公开（公告）日：2002-01-03

  The subject of the invention is the products of formula (I): 1 in which either R 1 represents halogen, hydroxyl, (C 1 -C 8 ) alkyloxy or (C 1 -C 12 ) acyloxy, and R 2 represents halogen or hydrogen, or R 1 and R 2 form together a double bond, Z is chosen from optionally substituted (C 1 -C 8 ) alkylthio, optionally substituted arylthio, (C 1 -C 8 ) alkyloxy, halogen, cyano, mercapto, thiocyanato and (CH 2 ) 0-1 —CO 2 H, optionally esterified, Y represents hydrogen or methyl, the dotted line in position 1-2 or 5-6 optionally representing a second bond, as well as their addition salts, their preparation process, the intermediates of this process and the pharmaceutical compositions containing them.

  本发明的主题是公式（I）的产物：1，其中R1表示卤素，羟基，（C1-C8）烷氧基或（C1-C12）酰氧基，R2表示卤素或氢，或者R1和R2一起形成双键，Z选择自可选取代的（C1-C8）烷硫基，可选取代的芳基硫基，（C1-C8）烷氧基，卤素，氰基，巯基，硫氰酸根和（CH2）0-1-CO2H，可选酯化，Y表示氢或甲基，位置1-2或5-6的点线可选地表示第二个键，以及它们的加成盐，制备过程，该过程的中间体和含有它们的药物组合物。
• COMPOUNDS HAVING CASPASE INHIBITORY ACTIVITY, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS AND FOR TREATING OR PREVENTING CORNEAL ENDOTHELIAL SYMPTOMS, DISORDERS, OR DISEASES, AND APPLICATION OF SAID PHARMACEUTICAL AGENT
  申请人：The Doshisha

  公开号：EP3639855A1

  公开（公告）日：2020-04-22

  The present invention provides a composition for treating or preventing corneal endothelial symptoms, disorders, or diseases that are attributed to TGF-β signaling in corneal endothelial cells. Provided by the present invention is a composition that includes a compound and that is for treating or preventing endothelial symptoms, disorders, or diseases, wherein, when the compound comes into contact with immortalized cells of Fuchs' corneal endothelial dystrophy, (i) said immortalized cells exhibit a cell survival rate (%) of approximately 90% or more after being cultured for 24-28 hours in Dulbecco's modified Eagle medium (DMEM) + 2% fetal bovine serum (FBS) + 1% penicillin/streptomycin (P/S), and (ii) the ratio of caspase 3/7 activity (%) in the presence of TGF-β with respect to said cellular survival rate (%) is at most 0.8 after being cultured for 24-28 hours in Dulbecco's modified Eagle medium (DMEM) + 2% fetal bovine serum (FBS) + 1% penicillin/streptomycin (P/S).

  本发明提供了一种用于治疗或预防角膜内皮症状、失调或疾病的组合物，这些症状、失调或疾病归因于角膜内皮细胞中的TGF-β信号传导。本发明提供了一种包含化合物的组合物，该组合物用于治疗或预防内皮症状、紊乱或疾病，其中，当该化合物与福氏角膜内皮营养不良症的永生化细胞接触时、(i) 在杜氏改良鹰培养基（DMEM）+2% 胎牛血清（FBS）+1% 青霉素/链霉素（P/S）中培养 24-28 小时后，所述永生化细胞表现出约 90% 或以上的细胞存活率（%），以及 (ii) 在 TGF-β 存在下，caspase 3/7 活性（%）与所述细胞存活率（%）之比至多为 0.在杜氏改良老鹰培养基（DMEM）+2% 胎牛血清（FBS）+1% 青霉素/链霉素（P/S）中培养 24-28 小时后，细胞存活率（%）最多为 0.8。
• DERIVES DE PREGNANE SANS SUBSTITUENT EN POSITION 17-ALPHA-, LEUR APPLICATION A TITRE DE MEDICAMENT, LEUR PROCEDE DE PREPARATION, LES INTERMEDIAIRES DE CE PROCEDE ET LES COMPOSITIONS LES CONTENANT
  申请人：HOECHST MARION ROUSSEL

  公开号：EP0898579B1

  公开（公告）日：2000-02-23
• Small molecule immunopotentiators and assays for their detection
  申请人：Valiante Nicholas

  公开号：US20110104186A1

  公开（公告）日：2011-05-05

  The invention provides immunostimulatory compositions comprising a small molecule immuno-potentiator (SMIP) compound and methods of administration thereof. Also provided are methods of administering a SMIP compound in an effective amount to enhance the immune response of a subject to an antigen. Further provided are novel compositions and methods of administering SMIP compounds alone or in combination with another agent for the treatment of cancer, infectious diseases and/or allergies/asthma. In a further aspect, the invention relates generally to methods of screening for small molecule immuno-modulatory compositions.
• US6274572B1
  申请人：——

  公开号：US6274572B1

  公开（公告）日：2001-08-14